ArticleGynecologic oncology reports2025
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): About three case reports.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive ovarian cancer affecting young women, typically associated with poor survival. We present three cases of SCCOHT and review the current literature regarding clinical features, diagnosis, management, and survival. Cases: Three patients aged 16, 29, and 39 years were treated for ovarian masses. None presented with hypercalcemia. In case 1, MRI findings mimicked a mucinous cystadenocarcinoma, while the other two cases appeared as benign ovarian tumors. Following initial surgery and histological diagnosis of SCCOHT, all patients received comprehensive radical surgery, multi-agent chemotherapy, radiotherapy, and autologous stem cell transplantation. Two patients remain recurrence-free at 5 and 20 years, while the third has a 10-month follow-up. Genetic testing was performed in two patients, revealing no constitutional mutations in SMARCA4 or related genes. Conclusions: These cases highlight the difficulty of establishing a preoperative diagnosis of SCCOHT. Unlike previous reports, our data suggest that intensive multimodal therapy can result in favourable outcomes for stage I SCCOHT. Further studies are needed to define optimal treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.